Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE4.1450
- TODAY'S CHANGE (%)0.0450 (1.0976%)
- Bid / Lots4.0600/ 20
- Ask / Lots4.1500/ 5
- Open / Previous Close4.1200 / 4.1000
- Day Range
- 52 Week Range
- Volume564,088
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 1648 | 4.12 |
| 09:34 ET | 1000 | 4.115 |
| 09:36 ET | 250 | 4.1 |
| 09:38 ET | 900 | 4.11 |
| 09:39 ET | 4200 | 4.095 |
| 09:41 ET | 10328 | 4.1 |
| 09:43 ET | 5000 | 4.1 |
| 09:48 ET | 2145 | 4.11 |
| 09:50 ET | 3000 | 4.13 |
| 09:52 ET | 2863 | 4.155 |
| 09:54 ET | 10354 | 4.16 |
| 09:56 ET | 3687 | 4.185 |
| 09:57 ET | 900 | 4.17 |
| 09:59 ET | 1700 | 4.17 |
| 10:01 ET | 503 | 4.15 |
| 10:03 ET | 7515 | 4.17 |
| 10:06 ET | 6200 | 4.15 |
| 10:08 ET | 900 | 4.1599 |
| 10:10 ET | 1427 | 4.155 |
| 10:12 ET | 1964 | 4.15 |
| 10:14 ET | 11739 | 4.12 |
| 10:15 ET | 2862 | 4.11 |
| 10:19 ET | 1000 | 4.105 |
| 10:21 ET | 1000 | 4.1054 |
| 10:24 ET | 1800 | 4.1099 |
| 10:26 ET | 5760 | 4.105 |
| 10:28 ET | 375 | 4.12 |
| 10:30 ET | 344 | 4.13 |
| 10:32 ET | 9241 | 4.1 |
| 10:35 ET | 100 | 4.105 |
| 10:37 ET | 800 | 4.11 |
| 10:39 ET | 500 | 4.11 |
| 10:42 ET | 300 | 4.1 |
| 10:44 ET | 3331 | 4.1 |
| 10:48 ET | 600 | 4.125 |
| 10:51 ET | 885 | 4.11 |
| 10:53 ET | 2100 | 4.11 |
| 10:55 ET | 800 | 4.11 |
| 10:57 ET | 551 | 4.099 |
| 11:00 ET | 900 | 4.1 |
| 11:02 ET | 400 | 4.12 |
| 11:04 ET | 100 | 4.12 |
| 11:06 ET | 5500 | 4.115 |
| 11:08 ET | 2804 | 4.125 |
| 11:09 ET | 7700 | 4.14 |
| 11:11 ET | 200 | 4.135 |
| 11:13 ET | 486 | 4.13 |
| 11:15 ET | 500 | 4.13 |
| 11:22 ET | 5167 | 4.125 |
| 11:24 ET | 100 | 4.125 |
| 11:26 ET | 700 | 4.1225 |
| 11:27 ET | 2464 | 4.125 |
| 11:31 ET | 1276 | 4.135 |
| 11:33 ET | 612 | 4.14 |
| 11:36 ET | 1498 | 4.14 |
| 11:38 ET | 15795 | 4.1108 |
| 11:40 ET | 8163 | 4.095 |
| 11:42 ET | 300 | 4.095 |
| 11:44 ET | 1100 | 4.105 |
| 11:49 ET | 500 | 4.115 |
| 11:51 ET | 400 | 4.115 |
| 11:58 ET | 1200 | 4.12 |
| 12:00 ET | 1318 | 4.13 |
| 12:02 ET | 500 | 4.13 |
| 12:07 ET | 5000 | 4.1326 |
| 12:09 ET | 14112 | 4.125 |
| 12:12 ET | 100 | 4.13 |
| 12:16 ET | 800 | 4.12 |
| 12:18 ET | 1499 | 4.125 |
| 12:23 ET | 100 | 4.115 |
| 12:25 ET | 1000 | 4.105 |
| 12:30 ET | 3300 | 4.115 |
| 12:32 ET | 2100 | 4.105 |
| 12:38 ET | 100 | 4.105 |
| 12:39 ET | 1700 | 4.125 |
| 12:41 ET | 200 | 4.125 |
| 12:45 ET | 100 | 4.125 |
| 12:48 ET | 5518 | 4.1295 |
| 12:50 ET | 400 | 4.125 |
| 12:52 ET | 100 | 4.125 |
| 12:57 ET | 2995 | 4.125 |
| 12:59 ET | 100 | 4.115 |
| 01:01 ET | 100 | 4.12 |
| 01:03 ET | 300 | 4.13 |
| 01:06 ET | 200 | 4.13 |
| 01:08 ET | 2688 | 4.125 |
| 01:10 ET | 1500 | 4.125 |
| 01:12 ET | 100 | 4.125 |
| 01:14 ET | 600 | 4.1291 |
| 01:15 ET | 14900 | 4.12 |
| 01:17 ET | 100 | 4.1212 |
| 01:19 ET | 4000 | 4.125 |
| 01:26 ET | 100 | 4.13 |
| 01:32 ET | 2779 | 4.153356 |
| 01:33 ET | 4191 | 4.13 |
| 01:46 ET | 310 | 4.13 |
| 01:48 ET | 15607 | 4.1303 |
| 01:50 ET | 14166 | 4.135 |
| 01:51 ET | 300 | 4.14 |
| 01:57 ET | 2794 | 4.15 |
| 02:02 ET | 3850 | 4.155 |
| 02:04 ET | 100 | 4.155 |
| 02:06 ET | 1135 | 4.15 |
| 02:08 ET | 4200 | 4.16 |
| 02:09 ET | 1845 | 4.16 |
| 02:13 ET | 200 | 4.16 |
| 02:15 ET | 2500 | 4.165 |
| 02:18 ET | 3245 | 4.155 |
| 02:20 ET | 200 | 4.155 |
| 02:22 ET | 100 | 4.155 |
| 02:24 ET | 100 | 4.155 |
| 02:26 ET | 800 | 4.155 |
| 02:27 ET | 900 | 4.145 |
| 02:31 ET | 2200 | 4.135 |
| 02:33 ET | 300 | 4.12 |
| 02:36 ET | 150 | 4.115 |
| 02:38 ET | 700 | 4.115 |
| 02:40 ET | 100 | 4.115 |
| 02:47 ET | 800 | 4.12 |
| 02:49 ET | 828 | 4.1252 |
| 02:51 ET | 500 | 4.135 |
| 02:54 ET | 100 | 4.135 |
| 02:56 ET | 2776 | 4.135 |
| 02:58 ET | 410 | 4.13 |
| 03:00 ET | 500 | 4.145 |
| 03:03 ET | 2100 | 4.145 |
| 03:05 ET | 100 | 4.135 |
| 03:07 ET | 4000 | 4.135 |
| 03:09 ET | 1200 | 4.135 |
| 03:12 ET | 100 | 4.135 |
| 03:14 ET | 3798 | 4.135 |
| 03:18 ET | 600 | 4.135 |
| 03:21 ET | 402 | 4.14 |
| 03:23 ET | 552 | 4.135 |
| 03:25 ET | 1742 | 4.13 |
| 03:27 ET | 1069 | 4.115 |
| 03:30 ET | 3526 | 4.125 |
| 03:32 ET | 100 | 4.125 |
| 03:34 ET | 2952 | 4.12 |
| 03:36 ET | 561 | 4.125 |
| 03:38 ET | 2399 | 4.11 |
| 03:39 ET | 20274 | 4.115 |
| 03:43 ET | 1300 | 4.12 |
| 03:45 ET | 300 | 4.12 |
| 03:48 ET | 900 | 4.115 |
| 03:50 ET | 3317 | 4.13 |
| 03:52 ET | 12202 | 4.135 |
| 03:54 ET | 900 | 4.135 |
| 03:56 ET | 1267 | 4.135 |
| 03:57 ET | 14301 | 4.155 |
| 03:59 ET | 37913 | 4.14 |
Sep 17, 2024
DJ Mereo BioPharma Group Down Over 9%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk, from 1:42PM ET on Tuesday Sep 17, 2024 by Dow Jones
1:42PM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 16, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 12:21PM ET on Monday Sep 16, 2024 by Dow Jones
12:21PM ET on Monday Sep 16, 2024 by Dow Jones
Sep 12, 2024
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference, from 5:35PM ET on Thursday Sep 12, 2024 by Dow Jones
5:35PM ET on Thursday Sep 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 658.5M | -12.5x | --- |
Arbutus Biopharma Corp | 843.9M | -8.7x | --- |
4D Molecular Therapeutics Inc | 844.5M | -4.9x | --- |
Immunome Inc | 959.1M | -2.6x | --- |
Perspective Therapeutics Inc | 884.7M | -9.0x | --- |
Dianthus Therapeutics Inc | 850.1M | -4.9x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $658.5M |
|---|---|
Revenue (TTM) | $10.6M |
Shares Outstanding | 153.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-0.33 |
Book Value | $0.47 |
P/E Ratio | -12.5x |
Price/Sales (TTM) | 62.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
